What are the effects of long-term use of Vigabatrin (vigabatrin) on children?

Vigabatrin (Vigabatrin) is an anti-epileptic drug mainly used to treat infantile spasms (West syndrome) and refractory focal epilepsy that are refractory to other drugs, especially in children. It has specific indications. This drug inhibits GABA transaminase, thereby increasing GABA concentration in the brain, thereby inhibiting abnormal nerve discharges. Although the efficacy is clear, long-term use in children still requires caution as it may cause some irreversible or serious side effects.

A more prominent problem is visual field loss. A significant proportion of children taking Vigabatrin for a long time may develop peripheral visual field defects and may even develop permanent visual field impairment. This adverse reaction is closely related to the cumulative dose of the drug and is irreversible in most cases. Therefore, regular vision and visual field examinations are recommended during treatment, and close monitoring is particularly necessary when the medication is used for more than a few months. However, in infants and young children, risk management is more challenging because of limited visual assessment.

In addition to vision problems, long-term use of Vigabatrin may also affect children's neuropsychological development. Some research reports show that some children experience abnormal behavior, depression, inattention, or delayed language development during the use of this drug. Although these side effects may not occur in all patients, parents and doctors should remain highly vigilant and evaluate whether the medication regimen needs to be adjusted or combined with other supportive treatments if necessary.

In general, Vigabatrin has unique value in controlling refractory epilepsy, but long-term use, especially in pediatric patients, should strictly weigh the efficacy and risks. While ensuring that epileptic seizures are effectively controlled, it is important to strengthen dynamic monitoring of vision, nervous system development, and psychological behavior, and achieve individualized medication and early intervention to reduce the probability of long-term side effects.

Reference materials:https://www.sabril.net/